A Clinical Study of T3011 in Subjects With Advanced Melanoma

Phase 1

Recruiting

• Conditions: Advanced Melanoma
• Interventions: Biological: T3011

• Registration Number: NCT06214156
• Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Brief Summary

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-09
• Study First Submitted QC: 2024-01-09
• Study First Posted: 2024-01-19
• Study Start: 2024-01-26
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-10
• Last Update Posted: 2025-04-11
• Primary Completion: 2025-09-30
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Subjects with advanced melanoma;
2. At least one measurable lesion;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
4. Expected survival > 12 weeks;
5. Laboratory inspection meets the requirements;
6. For women of childbearing potential, the serum pregnancy test results must be negative within 7 days prior to the first dose，and effective contraceptive measures must be taken from signing the informed consent form (ICF) until at least 6 months after the last dose;
7. Male subjects of childbearing potential agree to use effective contraception from signing the ICF until at least 6 months after the last dose; In addition, male subjects must agree not to donate sperm during this period;
8. Understand and voluntarily sign the ICF，willing and able to comply with all experimental requirements.

Exclusion Criteria

1. Subjects who have received other antitumor therapy within the prescribed time prior to the first dose;
2. Subjects with a history of other malignancies within the prescribed time prior to the start of study treatment.
3. At screening, subjects with a history or evidence of high risk cardiovascular disease;
4. Subjects with persistent or active infection requiring intravenous anti-infective therapy;
5. Subjects with autoimmune diseases or a history of autoimmune diseases;
6. Subjects with known psychiatric disorders that may affect trial compliance;
7. Subjects who have pleural effusion, pericardial effusion, or ascites before starting treatment and require puncture drainage, or who had received puncture drainage within the specified time before starting the study treatment;
8. Subjects requiring systemic treatment with anti-HSV drugs during the study period;
9. Subjects who have received live or attenuated vaccines within the prescribed time prior to the first dose, or who plan to receive such vaccines during the study period; Subjects who have received any tumor vaccine in the past;
10. Subjects who had undergone major surgery within the prescribed time before the first dose，and had not recovered from surgery-related adverse reactions or were still in the postoperative recovery period，or who plan to undergo major surgery during the study period;
11. Subjects with a history of drug use，drug abuse or alcohol abuse within the year prior to signing the ICF;
12. Female subjects who are pregnant or breastfeeding, or planning to conceive or have children during the study period;
13. The investigator considers it inappropriate to participate in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
T3011	T3011	-

Primary Outcome Measures

Name	Time	Method
Objective response rate(ORR)	Approximately 2 years	Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1
Incidence of Treatment-Emergent Adverse Events	Approximately 2 years	Adverse event type, incidence, duration

Secondary Outcome Measures

Name	Time	Method
Disease control rate (DCR)	Approximately 2 years	DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease
Duration of remission (DOR)	Approximately 2 years	DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response to the date of disease progression per RECIST v1.1 or death from any cause.
Progression-free survival (PFS)	Approximately 2 years	From the start date of study treatment to the date of progression disease or death , whichever occurred first.
Overall Survival (OS)	Approximately 2 years	Determination of the overall survival time of all patients

Trial Locations

Locations (7)

The First Affiliated Hospital of Bengbu Medical College; 🇨🇳 Bengbu, China

Jilin Cancer Hospital; 🇨🇳 Changchun, China

Beijing Cancer Hospital; 🇨🇳 Beijing, China

Chengdu Shangjin Nanfu Hospital; 🇨🇳 Chengdu, China

Fujian Cancer Hospital; 🇨🇳 Fuzhou, China

The Third People's Hospital of Zhengzhou; 🇨🇳 Zhengzhou, China

Sun Yat-sen University Cancer Center; 🇨🇳 Zhongshan, China